Global Hemophilia Market Report: 2013 Edition
Hemophilia is a disorder in which the blood does not clot properly, leading to extended bleeding. The bleeding can be external or internal, especially in the knees, ankles, and elbows. There are two types of hemophilia: type A and type B. The market has been growing since past several years mainly due to improvement in technology, discovery of new coagulation factors, proteins, and plasma concentrates which are being used for treating chronic diseases and medical conditions.
As more people suffer with Hemophilia A in comparison with Hemophilia B and Inhibitors, the Hemophilia A market is the largest in the world. The US accounts for the major population suffering with hemophilia globally.
The key trends observed within the market include inclination towards prophylaxis, long-acting factor VIII and IX development and growing penetration of rFVIII products in emerging markets which is a opportunity for manufacturers. On the development front, there has been an increase in the launch of new products by various companies. But there are certain challenges which the industry is facing as of now which include risk of antibody neutralization, emerging challenges for developing nations and rising cost of hemophilia treatment. The major factors which will contribute in the growth of the industry include rising male population, increasing expenditure on healthcare and increasing new patient registration.
The report studies the hemophilia market on a global scale and its various segments. The competition in the global hemophilia market is intense with few large players viz. Baxter, Grifols, Pfizer and Nova Noridisk. The competitive landscape along with the company profiles of the leading players in the market is discussed in detail.
By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
As more people suffer with Hemophilia A in comparison with Hemophilia B and Inhibitors, the Hemophilia A market is the largest in the world. The US accounts for the major population suffering with hemophilia globally.
The key trends observed within the market include inclination towards prophylaxis, long-acting factor VIII and IX development and growing penetration of rFVIII products in emerging markets which is a opportunity for manufacturers. On the development front, there has been an increase in the launch of new products by various companies. But there are certain challenges which the industry is facing as of now which include risk of antibody neutralization, emerging challenges for developing nations and rising cost of hemophilia treatment. The major factors which will contribute in the growth of the industry include rising male population, increasing expenditure on healthcare and increasing new patient registration.
The report studies the hemophilia market on a global scale and its various segments. The competition in the global hemophilia market is intense with few large players viz. Baxter, Grifols, Pfizer and Nova Noridisk. The competitive landscape along with the company profiles of the leading players in the market is discussed in detail.
By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
1. HEMOPHILIA: AN OVERVIEW
Sign & Symptoms
Types of Hemophilia
Treatment
2. MARKET OVERVIEW
2.1 Global Hemophilia Market
Market Value
Patient Volume
2.2 Hemophilia Market by Segments
2.2.1 Hemophilia A
Market Value
Patient Volume
Key Products Comparison
FVIII Market
2.2.2 Hemophilia B
Market Value
Patient Volume
Key Products Comparison
FIX Market
2.2.3 Hemophilia with Inhibitor
Market Value
Patient Volume
Key Products
2.2.4 Von Willebrand Disease
2.3 Hemophilia Market by Region
2.3.1 Australia
2.3.2 The US
Market Value
Patient Volume
Market Segments
FVIII Market
FIX Market
3. MARKET DYNAMICS
3.1 Key Trends
3.1.1 Shift towards Prophylaxis
3.1.2 Long-Acting Factor VIII and IX Development
3.1.3 Rising Penetration of rFVIII Products in Emerging Markets
3.2 Growth Drivers
3.2.1 Rising Male Population
3.2.2 Increasing Expenditure on Healthcare
3.2.3 Increasing New Patient Registration
3.3 Significant Developments
3.3.1 Baxter Announced ADVATE Approval in China
3.3.2 Baxter Expands Access to Recombinant FVIII Hemophilia Treatment in Brazil
3.3.3 Novo Nordisk Files New Hemophilia Drug in EU, US
3.4 Challenges
3.4.1 Risk of Antibody Neutralization
3.4.2 Emerging Challenges for Developing Nations
3.4.3 Rising Cost of Hemophilia Treatment
4. COMPETITIVE SCENARIO
Market Share
Product Comparison
5. COMPANY PROFILES
5.1 Baxter International Inc.
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
Advancement of Core Portfolio
Expansion of Product Portfolio
5.2 Grifols
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
Expansion in Other Geographic Regions
Growth through Mergers & Acquisitions
5.3 Novo Nordisk
5.3.1 Business Description
5.3.2 Financial Highlights
5.3.3 Business Strategies
Product Innovation
5.4 Pfizer, Inc.
5.4.1 Business Overview
5.4.2 Financial Highlights
5.4.3 Business Strategies
Expansion in Emerging Markets
Growth through Acquisitions
6. MARKET OUTLOOK
6.1 Market Forecast
6.2 Forecast Methodology
6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis
Sign & Symptoms
Types of Hemophilia
Treatment
2. MARKET OVERVIEW
2.1 Global Hemophilia Market
Market Value
Patient Volume
2.2 Hemophilia Market by Segments
2.2.1 Hemophilia A
Market Value
Patient Volume
Key Products Comparison
FVIII Market
2.2.2 Hemophilia B
Market Value
Patient Volume
Key Products Comparison
FIX Market
2.2.3 Hemophilia with Inhibitor
Market Value
Patient Volume
Key Products
2.2.4 Von Willebrand Disease
2.3 Hemophilia Market by Region
2.3.1 Australia
2.3.2 The US
Market Value
Patient Volume
Market Segments
FVIII Market
FIX Market
3. MARKET DYNAMICS
3.1 Key Trends
3.1.1 Shift towards Prophylaxis
3.1.2 Long-Acting Factor VIII and IX Development
3.1.3 Rising Penetration of rFVIII Products in Emerging Markets
3.2 Growth Drivers
3.2.1 Rising Male Population
3.2.2 Increasing Expenditure on Healthcare
3.2.3 Increasing New Patient Registration
3.3 Significant Developments
3.3.1 Baxter Announced ADVATE Approval in China
3.3.2 Baxter Expands Access to Recombinant FVIII Hemophilia Treatment in Brazil
3.3.3 Novo Nordisk Files New Hemophilia Drug in EU, US
3.4 Challenges
3.4.1 Risk of Antibody Neutralization
3.4.2 Emerging Challenges for Developing Nations
3.4.3 Rising Cost of Hemophilia Treatment
4. COMPETITIVE SCENARIO
Market Share
Product Comparison
5. COMPANY PROFILES
5.1 Baxter International Inc.
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
Advancement of Core Portfolio
Expansion of Product Portfolio
5.2 Grifols
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
Expansion in Other Geographic Regions
Growth through Mergers & Acquisitions
5.3 Novo Nordisk
5.3.1 Business Description
5.3.2 Financial Highlights
5.3.3 Business Strategies
Product Innovation
5.4 Pfizer, Inc.
5.4.1 Business Overview
5.4.2 Financial Highlights
5.4.3 Business Strategies
Expansion in Emerging Markets
Growth through Acquisitions
6. MARKET OUTLOOK
6.1 Market Forecast
6.2 Forecast Methodology
6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis
LIST OF CHARTS
Types of Hemophilia
Worldwide Patients Treated with Hemophilia (2010-2012E)
Global Hemophilia Treatment Market Revenues (2008-2013E)
Worldwide Patients Treated with Hemophilia A (2010-2012E)
Global Hemophilia A Market Size (2010-2012E)
Global Recombinant FVIII Market Revenues (2005-2012E)
Worldwide Patients Treated with Hemophilia B (2010-2012E)
Global Hemophilia B Market Size (2010-2012E)
Global Recombinant FIX Market Size (2006-2012E)
Global Recombinant FIX Consumption (2005-2011)
Global Recombinant FIX Consumption Market Share (2011)
Worldwide Patients Treated with Inhibitor (2010-2012E)
Global Inhibitor Market Size (2010-2013E)
Demand of Plasma Derived Factor IX in Australia (2008-2012)
Demand of Recombinant Factor IX in Australia (2008-2012)
Number of Hemophilia Patients Treated in the US (2010-2012E)
The US Hemophilia Market Value (2010-2012E)
Global Male Population (2005-2014F)
Healthcare Expenditure Worldwide (2005-2012E)
New Patient Registrations in Global Bleeding Disorders Market (2008-2012)
Global Hemophilia Market Share (2011)
Global Recombinant Coagulation (FVII, FVIII, FIX) Market (2011)
Global Recombinant FVIII Market Share (2012E)
Baxter’s Revenue by Business Segments (2012)
Baxter’s Revenues and Net Income (2008-2012)
Grifols Revenue Share by Business Segments (2012)
Grifols Revenue Share by Geographical Segments (2012)
Grifols’ Revenues & Net Profit (2008-2012)
Novo Nordisk’s Revenue Share by Business Segments (2012)
Novo Nordisk’s Revenue Share by Region (2012)
Sales and Net Income of Novo-Nordisk (2008-2012)
Pfizer’s Revenue Share by Business Segments (2012)
Pfizer’s Revenue Share by Geographical Segments (2012)
Pfizer’s Revenues & Net Income (2008-2012)
Global Hemophilia Treatment Market Forecast (2011-2016F)
Types of Hemophilia
Worldwide Patients Treated with Hemophilia (2010-2012E)
Global Hemophilia Treatment Market Revenues (2008-2013E)
Worldwide Patients Treated with Hemophilia A (2010-2012E)
Global Hemophilia A Market Size (2010-2012E)
Global Recombinant FVIII Market Revenues (2005-2012E)
Worldwide Patients Treated with Hemophilia B (2010-2012E)
Global Hemophilia B Market Size (2010-2012E)
Global Recombinant FIX Market Size (2006-2012E)
Global Recombinant FIX Consumption (2005-2011)
Global Recombinant FIX Consumption Market Share (2011)
Worldwide Patients Treated with Inhibitor (2010-2012E)
Global Inhibitor Market Size (2010-2013E)
Demand of Plasma Derived Factor IX in Australia (2008-2012)
Demand of Recombinant Factor IX in Australia (2008-2012)
Number of Hemophilia Patients Treated in the US (2010-2012E)
The US Hemophilia Market Value (2010-2012E)
Global Male Population (2005-2014F)
Healthcare Expenditure Worldwide (2005-2012E)
New Patient Registrations in Global Bleeding Disorders Market (2008-2012)
Global Hemophilia Market Share (2011)
Global Recombinant Coagulation (FVII, FVIII, FIX) Market (2011)
Global Recombinant FVIII Market Share (2012E)
Baxter’s Revenue by Business Segments (2012)
Baxter’s Revenues and Net Income (2008-2012)
Grifols Revenue Share by Business Segments (2012)
Grifols Revenue Share by Geographical Segments (2012)
Grifols’ Revenues & Net Profit (2008-2012)
Novo Nordisk’s Revenue Share by Business Segments (2012)
Novo Nordisk’s Revenue Share by Region (2012)
Sales and Net Income of Novo-Nordisk (2008-2012)
Pfizer’s Revenue Share by Business Segments (2012)
Pfizer’s Revenue Share by Geographical Segments (2012)
Pfizer’s Revenues & Net Income (2008-2012)
Global Hemophilia Treatment Market Forecast (2011-2016F)
LIST OF TABLES
Revenues of Key Products in Hemophilia A Treatment Market (2011-2016F)
Products for Hemophilia A Treatment
Products for Treatment of Hemophilia B
Inhibitor Treatment (2010-2012E)
US Hemophilia Market by Segments (2010-2012E)
Volume of FVIII Market in the US (2008-2012)
US FIX Consumption (2005-2011)
US Factor (M IU) Consumption by Treatment Type and Patient Age (2012-2020)
Hemophilia A patients by Treatment Category (2012)
Long Acting FIX & FVIII in Early and Late-Stage Development
% Conversion to Recombinant Factor VIII Products in Selected Countries (2011)
Competition in Hemophilia A Market – Emerging Products
Competition in Hemophilia B Market – Emerging Products
Competition in Inhibitor Market – Emerging Products
Competition in von Willebrand Market – Emerging Products
Dependent & Independent Variables (2008-2012)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output
Revenues of Key Products in Hemophilia A Treatment Market (2011-2016F)
Products for Hemophilia A Treatment
Products for Treatment of Hemophilia B
Inhibitor Treatment (2010-2012E)
US Hemophilia Market by Segments (2010-2012E)
Volume of FVIII Market in the US (2008-2012)
US FIX Consumption (2005-2011)
US Factor (M IU) Consumption by Treatment Type and Patient Age (2012-2020)
Hemophilia A patients by Treatment Category (2012)
Long Acting FIX & FVIII in Early and Late-Stage Development
% Conversion to Recombinant Factor VIII Products in Selected Countries (2011)
Competition in Hemophilia A Market – Emerging Products
Competition in Hemophilia B Market – Emerging Products
Competition in Inhibitor Market – Emerging Products
Competition in von Willebrand Market – Emerging Products
Dependent & Independent Variables (2008-2012)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output
